YURAK YETISHMOVCHILIGIDA TEMIR TANQISLIGINING PATOFIZIOLOGIYASI
##article.subject##:
temir tanqisligi, yurak yetishmovchiligi, mutlaq temir tanqisligi, funksional temir tanqisligi, hepsidin, tizimli yallig‘lanish, mitoxondrial disfunksiya, tomir ichiga temir yuborish terapiyasi, ferrik karboksimaltos, anemiya, jismoniy faollikka bardoshsizlik, hayot sifati##article.abstract##
Temir tanqisligi (TT) yurak yetishmovchiligi (YY) bilan og‘rigan bemorlar orasida keng tarqalgan va klinik jihatdan muhim hamroh kasallik bo‘lib, stabil YY bo‘lgan bemorlarning 50% gacha va o‘tkir YY holatlarida 80% gacha qamrab oladi. Ushbu sharhda YYda TTning patofiziologiyasi, jumladan, mutlaq temir tanqisligi (MTT) va funksional temir tanqisligi (FTT) ko‘rib chiqiladi. YYda TTning asosiy mexanizmlari tizimli yallig‘lanish bilan bog‘liq bo‘lib, bu geptsidin darajasining oshishiga, temirning yutilishi buzilishiga va makrofaglardagi temirning to‘planishiga olib keladi, natijada muhim hujayra jarayonlari uchun temir yetishmovchiligi yuzaga keladi. Bundan tashqari, oshqozon-ichak tizimidagi turg‘unlik va proton nasos ingibitorlari kabi dorilarni qo‘llash temirning yutilish muammolarini yanada kuchaytiradi. Temir tanqisligi mitoxondriyal funksiyaga va energiya ishlab chiqarishga salbiy ta'sir ko‘rsatib, jismoniy faollikning pasayishi, mushak charchoqlari va hayot sifatining yomonlashuviga olib keladi. Shuningdek, TT anemiyaning mavjudligidan qat’i nazar, bemorlarda kasalxonaga yotqizilish xavfi va o‘lim ko‘rsatkichlarini oshiradi. Temir tanqisligini davolash bo‘yicha usullar, xususan, ferrik karboksimaltos (FCM) kabi tomir ichiga yuboriladigan preparatlar simptomlarning, jismoniy faollikning va bemorlarning umumiy natijalarining sezilarli darajada yaxshilanishini ko‘rsatdi. YYda temir tanqisligini bartaraf etish klinik natijalarni va bemorlarning hayot sifatini yaxshilash uchun muhim terapevtik maqsadga aylandi.
Библиографические ссылки
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., ... & Ponikowski, P. (2009). Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine, 361(25), 2436-2448.
Camaschella, C., Nai, A., & Silvestri, L. (2020). Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica, 105(2), 260.
Cappellini, M. D., Comin‐Colet, J., de Francisco, A., Dignass, A., Doehner, W., Lam, C. S., ... & IRON CORE Group. (2017). Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American journal of hematology, 92(10), 1068-1078.
Longo, D. L., & Camaschella, C. (2015). Iron-deficiency anemia. N Engl J Med, 372(19), 1832-43.
Ganz, T. (2011). Hepcidin and iron regulation, 10 years later. Blood, The Journal of the American Society of Hematology, 117(17), 4425-4433.
Jankowska, E. A., Tkaczyszyn, M., Suchocki, T., Drozd, M., von Haehling, S., Doehner, W., ... & Ponikowski, P. (2016). Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials. European journal of heart failure, 18(7), 786-795.
McDonagh, T., & Macdougall, I. C. (2015). Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?. European journal of heart failure, 17(3), 248-262.
Packer, M., Anker, S. D., Butler, J., Cleland, J. G., Kalra, P. R., Mentz, R. J., & Ponikowski, P. (2024). Identification of three mechanistic pathways for iron-deficient heart failure. European Heart Journal, ehae284.
Pasricha, S. R., Tye-Din, J., Muckenthaler, M. U., & Swinkels, D. W. (2021). Iron deficiency. The Lancet, 397(10270), 233-248.
Ponikowski, P., Kirwan, B. A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., ... & Jankowska, E. A. (2019). Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure. European journal of heart failure, 21(12), 1651-1658.
Rizaev, J. A., & Agababyan, I. R. (2021). YA Ismoilova Activities of clinics specializing in the treatment of patients with chronic heart disease in the world (references). Journal of Biomedicine and Practice, 6(6), 184-191.
von Haehling, S., Ebner, N., Evertz, R., Ponikowski, P., & Anker, S. D. (2019). Iron deficiency in heart failure: an overview. JACC: Heart Failure, 7(1), 36-46.
Ризаев Ж.А., Агабабян И.Р., Ярашева З.Х., & Мухамедова М.Г. (2022). ЗНАЧЕНИЕ КОМОРБИДНЫХ СОСТОЯНИЙ В РАЗВИТИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У БОЛЬНЫХ ПОЖИЛОГО И СТАРЧЕСКОГО ВОЗРАСТА. Достижения науки и образования, (1 (81)), 75-79.
